Stephens analyst Drew Jones reiterated a Buy rating on NeoGenomics (NEO) yesterday and set a price target of $21. The company’s shares closed yesterday at $18.45, close to its 52-week high of $19.04.
Jones has an average return of 30.6% when recommending NeoGenomics.
According to TipRanks.com, Jones is ranked #539 out of 5188 analysts.
The the analyst consensus on NeoGenomics is currently a Moderate Buy rating.
See today’s analyst top recommended stocks >>
NeoGenomics’ market cap is currently $1.72B and has a P/E ratio of 304.96. The company has a Price to Book ratio of 5.65.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NeoGenomics, Inc. provides cancer diagnostics and pharma services. It operates through a network of cancer focused testing laboratories to provide genetic and molecular testing services.
